HOME >> MEDICINE >> NEWS
Treatment-Resistant Depression: Results of Latest Electromagnetic Stimulation Study Show Promise

eters below the brain's surface. Unlike ECT for depression, rTMS does not require anesthesia or analgesics."

Study subjects were antidepressant-free for one week prior to rTMS and received 10 daily treatments (10 trains of five seconds each, 25 seconds apart) at a frequency of 10 Hz. Seventy-eight percent of patients experienced mild-moderate discomfort at the site of stimulation, two patients who experienced severe pain in the treatment site dropped out of the study and eight percent of patients experienced a posttreatment headache.

The mean age of patients treated was 52 years. " rTMS seems most promising for older adults and for treatment-resistant patients with depression," says Dr. McDonald, who directs the Fuqua Center for Late-Life Depression at Wesley Woods.

Also collarborating on the study were Charles M. Epstein, M.D., associate professor of neurology at Emory; Liquong He, M.D., formerly with Emory; Autumn L. Clark, B.S., study coordinator in Emory's department of psychiatry and behavioral sciences; Fred A. Marstellar, Ph.D., associate professor of psychiatry and behavioral sciences at Emory; and John Woodard, Ph.D., of the Georgia State University Memory Assessment Clinic.

The study was supported by a private grant from the Fuqua Foundation.


'"/>

Contact: Sarah Goodwin
sgoodwi@emory@emory.edu
404-727-3366
Emory University Health Sciences Center
17-May-1999


Page: 1 2

Related medicine news :

1. Heart transplant survival: Results may be key to rejection prevention, detection, treatment
2. Docetaxel versus paclitaxel in breast cancer Results of worlds first head to head trial
3. Results from first clinical trial using GVG to treat addiction
4. Results of first chronic treatment study with oral EXANTA(TM) (ximelagatran)
5. Media Advisory-- Results of California autism epidemiology study to be unveiled
6. Results of Yale study confirm aspirin helpful in preventing a first heart attack
7. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
8. Yale study shows way to re-stimulate brain cell growth: Results could boost understanding of Alzheimers, other brain disorders
9. Results of NUVANCE phase I/II asthma trial presented
10. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
11. UI Study Yields Encouraging Results For New Breast Cancer Treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/5/2016)... , ... February 05, 2016 , ... ... domestic franchisees of Popeyes Louisiana Kitchen restaurants, launched the 14th annual “Appetite for ... kids and adults with muscular dystrophy, ALS and related diseases that severely limit ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... After years ... General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief ... Hospital. He successfully completed his first three-year term as chief and began a second ...
(Date:2/5/2016)... OR (PRWEB) , ... February 05, 2016 , ... The ... modern technology, such water may be safer than regular municipal or well water. The ... and radio host Sharon Kleyne, could go a long way toward increasing public acceptance ...
(Date:2/5/2016)... ... 2016 , ... Pivot Point Consulting, a leading national Healthcare ... Services for HIT Implementation Support & Staffing report with an outstanding score of ... healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 clinics. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. ... announces that it is now welcoming orthodontist, Dr. Amanda Cheng, to the practice. ... range of oral health care, including general dentistry, cosmetic treatments, periodontics, implant ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016  SciClone Pharmaceuticals, ... announced it has entered into a settlement agreement ... (SEC) fully resolving the SEC,s investigation into possible ... Under the terms of the settlement agreement, SciClone ... million, including disgorgement, pre-judgment interest and a penalty.  ...
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
(Date:2/4/2016)... -- AMRI (NASDAQ:  AMRI) today announced that Anthony J. Maddaluna ... Pfizer Global Supply, has been elected to the AMRI Board ... the Company announced that Mr. Gabe Leung , a ... retired from the AMRI Board of Directors in order to ... William S. Marth , President and CEO. ...
Breaking Medicine Technology:
Cached News: